Gülşen Kocaman1, Neşe Kahraman2, Banu Gürkan Köseoğlu2, Başar Bilgiç3, Zeliha Matur4, Mustafa Ertaş5, Yeşim Gülşen3, Betül Baykan Baykal3. 1. Department of Neurology, Bezmialem Vakıf University, Faculty of Medicine, İstanbul, Turkey. 2. Department of Maxillofacial Surgery, İstanbul University, İstanbul Faculty of Dentistry, İstanbul, Turkey. 3. Department of Neurology, İstanbul University, İstanbul Medical Faculty, İstanbul, Turkey. 4. Department of Neurology, İstanbul Bilim University, Faculty of Medicine, İstanbul, Turkey. 5. Neurology, Private Office, İstanbul, Turkey.
Abstract
Introduction: Migraine and temporomandibular disorders (TMD) are both common diseases and TMD are reported as a risk factor in migraine progression. OnabotulinumtoxinA is used in the treatment of chronic migraine (CM), and also has a potential role in TMD treatment. In this study, it is aimed to compare the efficacy of onabotulinumtoxinA treatment in CM patients with and without TMD. Methods: In this retrospective study, 30 CM patients (age range: 18-65 years), satisfying the inclusion and follow-up criteria in their medical records were investigated. The PREEMPT injection protocol was taken as reference and onabotulinumtoxinA 155-195 U with fixed-dose has been administered into 31 specific sites within the head/neck muscles in included subjects. Two cycles of treatment were assessed in all patients at the baseline and 12 weeks later. The headache diaries, which were completed routinely one month before, and during 6 months follow-up after the treatment, were assessed. The effect of onabotulinumtoxinA treatment was compared between CM patients with and without TMD/bruxism. Results: Of 30 female patients, 17 had concomitant TMD. In week 24, there were significant improvement in the groups with and without TMD regarding to the mean change of frequencies in the days with migraine compared to the initial findings (p<0.001). However, there was no significant difference between the two groups. Conclusions: OnabotulinumtoxinA is an effective and safe treatment for CM. Its efficacy appears to be similar in CM patients with and without TM, speculating that the comorbidity of TMD did not play a role for the treatment response.
Introduction: Migraine and temporomandibular disorders (TMD) are both common diseases and TMD are reported as a risk factor in migraine progression. OnabotulinumtoxinA is used in the treatment of chronic migraine (CM), and also has a potential role in TMD treatment. In this study, it is aimed to compare the efficacy of onabotulinumtoxinA treatment in CMpatients with and without TMD. Methods: In this retrospective study, 30 CMpatients (age range: 18-65 years), satisfying the inclusion and follow-up criteria in their medical records were investigated. The PREEMPT injection protocol was taken as reference and onabotulinumtoxinA 155-195 U with fixed-dose has been administered into 31 specific sites within the head/neck muscles in included subjects. Two cycles of treatment were assessed in all patients at the baseline and 12 weeks later. The headache diaries, which were completed routinely one month before, and during 6 months follow-up after the treatment, were assessed. The effect of onabotulinumtoxinA treatment was compared between CMpatients with and without TMD/bruxism. Results: Of 30 female patients, 17 had concomitant TMD. In week 24, there were significant improvement in the groups with and without TMD regarding to the mean change of frequencies in the days with migraine compared to the initial findings (p<0.001). However, there was no significant difference between the two groups. Conclusions: OnabotulinumtoxinA is an effective and safe treatment for CM. Its efficacy appears to be similar in CMpatients with and without TM, speculating that the comorbidity of TMD did not play a role for the treatment response.
Authors: H C Diener; D W Dodick; S K Aurora; C C Turkel; R E DeGryse; R B Lipton; S D Silberstein; M F Brin Journal: Cephalalgia Date: 2010-03-17 Impact factor: 6.292
Authors: S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin Journal: Cephalalgia Date: 2010-03-17 Impact factor: 6.292
Authors: Fernanda Mara de Paiva Bertoli; Sérgio A Antoniuk; Isac Bruck; Guilherme R P Xavier; Danielle C B Rodrigues; Estela Maris Losso Journal: Arq Neuropsiquiatr Date: 2007-06 Impact factor: 1.420